ProMIS Neurosciences Inc PMN

CA Biotechnology

$13.72 ▼ -8.04% ($-1.20)

🎈 Low Float 🗓️ Earnings Next Week

Open $14.68

Prev Close $14.92

Day Range $13.47 – $14.93

52W Range $6.27 – $27.40

Market Cap $123.04M

Beta -0.22

EPS (TTM) $-18.59

📋 Company Profile

Industry	Biotechnology
Country	CA
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2017-04-03
Shares Out.	8,970,000
Website	promisneurosciences.com/ ↗
Phone	14168476898
Employees	11
Net Income	-$8.2M
Total Assets	$67.4M
Total Liabilities	$6.7M
Equity	$60.7M

About ProMIS Neurosciences Inc

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

ProMIS Neurosciences Inc is a publicly traded company under the ticker symbol PMN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.